November 16, 2007 — SITTARD/LEIDEN, THE NETHERLANDS — DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. today announced a PER.C6(R) license agreement with Daiichi Sankyo Ltd. This license agreement allows Daiichi Sankyo to use the PER.C6(R) cell line in its early stage research to identify new antibodies and for the production of pre-clinical grade material. Financial details were not disclosed.
About the PER.C6(R) Technology Platform
Crucell’s PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability, and productivity under serum-free culture conditions.
Crucell N.V. is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The company has a broad
development pipeline, with several Crucell products based on its unique PER.C6(R) production technology. The company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, Sanofi Aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden (The Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea, and the U.S. The company employs more than a 1,000 people.
About DSM Biologics
DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology and services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6(R) human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics’ FDA-approved
facility in Groningen, The Netherlands, was established in 1986 and has a strong track record in using a broad range of cell lines (PER.C6(R), CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has a wide range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6(R) human cell line and DSM’s manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. DSM Biologics is represented in Japan by Asahi Glass & Co, Ltd.
DSM creates innovative products and services in life sciences and materials sciences, contributing to the quality of life. DSM’s products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and enjoyable way of living. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. The company strategy, Vision 2010